← All articles

Semax vs Selank: Differences, Study Results and Safety Gaps

Bookmark this page

Save this article in your browser so you can find it again:

  • Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
  • iPhone or iPad: In Safari, tap Share, then Add Bookmark.
  • Android: In Chrome, open the menu and tap the star.

Other browsers may use a different menu.

Semax vs Selank is an evidence question before it is a question of which peptide is “better.” The two have different molecular origins, and their studies examine different populations and outcomes. A small human brain-imaging experiment compared them, but it did not establish which improves anxiety, ADHD symptoms or everyday cognitive functioning.

Direct answer: The available sources do not support a clinical winner. Selank has small anxiety studies with important design limitations. Semax research and proposed indications do not establish an ADHD treatment effect. Findings from either compound also do not establish the benefits or safety of using them together.

Publisher disclosure: Bio Research LLC operates Bio Peptides Labs. This commercially interested, AI-assisted summary is not an independent scientific review. It evaluates published evidence, including source-access limitations, rather than recommending treatment.

Semax versus Selank evidence map asks which peptide, which population and which endpoint were studied. Brain imaging in healthy volunteers is distinct from symptom relief or combination efficacy.
The human imaging comparison measured biological signals. Population and endpoint differences prevent a clinical ranking or a claim about combined treatment.

How are Semax and Selank different?

Semax is an ACTH-related seven-amino-acid peptide. Selank is a seven-amino-acid peptide derived from tuftsin with an added Pro-Gly-Pro segment. These different structures are a reason to examine each compound's experiments separately, not a basis for assigning one to “focus” and the other to “calm.” FDA Semax identity evaluation, original Selank experimental paper

Research evidence map

Question

Semax

Selank

Molecular origin

ACTH-related peptide

Tuftsin-derived peptide

Human evidence examined here

Healthy-volunteer brain imaging; FDA appraisal of other proposed uses

Healthy-volunteer imaging and small anxiety studies

Common unsupported inference

A proposed mechanism establishes ADHD symptom relief

Similar scores in a small comparison prove equivalent effectiveness or greater safety

Shared gap

Patient-centered comparative evidence

Patient-centered comparative evidence

Mechanistic findings help generate research questions. For example, a Selank experiment measured changes in neurotransmission-related gene expression in rat frontal cortex. It did not test anxiety relief in patients or establish that Selank acts like a particular licensed anxiety medicine. Volkova and colleagues, 2016

What does the direct comparison show?

Panikratova and colleagues studied 52 healthy participants in Semax, Selank and placebo groups. Resting-state functional MRI was assessed before exposure and shortly afterward. The paper reported differences in connectivity involving the right amygdala and temporal cortex. Original 2020 publisher abstract

This is a direct comparison of short-term biological signals. It is not a trial of people with ADHD or an anxiety disorder, and the groups received Semax or Selank—not a combined Semax–Selank treatment. A connectivity change has no automatic interpretation as better concentration, less distress or improved daily functioning.

The distinction matters when a comparison page claims that one peptide is “stronger.” Stronger on which prespecified outcome, in which population, over what period? The imaging study cannot answer a clinical ranking question that it did not test.

What can the anxiety and ADHD sources establish?

Research evidence map

Source

What was studied

Main interpretive limit

Zozulia, 2008

Selank versus medazepam in 62 people with generalized anxiety disorder or neurasthenia

Abstract-level access; limited methods detail

Medvedev, 2014

Open-label comparison of Selank and phenazepam in 60 adults with anxiety-spectrum disorders

No placebo; short observation; outcomes varied by assessment time

Tsai, 2007

Proposed Semax rationale for ADHD and Rett syndrome

Hypothesis paper, not a patient trial

The 2008 Selank abstract reports similar anxiolytic effects between its groups. That wording does not establish formal noninferiority: a study must specify and justify an acceptable difference and analyze it appropriately. The abstract alone does not allow a complete appraisal of allocation, masking or adverse-event reporting.

The 2014 Russian-language study reported improvement in both groups. Some early outcomes favored phenazepam, while some later outcomes favored Selank. Its open-label design makes expectation and assessment bias relevant. Nasal dryness was reported in the Selank group. The paper acknowledges Peptogen and Russian Foundation for Basic Research support. These findings warrant further study rather than a blanket claim of proven effectiveness without side effects.

For Semax, the frequently cited ADHD paper proposes a biological rationale; it does not report an ADHD trial. FDA's 2026 evaluation did not assess ADHD because it did not find supporting literature for that use. The evaluation also describes translation-related exclusions, so its scope should not be stretched into proof that no Russian clinical work exists. FDA Semax review

Is there evidence for taking Semax and Selank together?

A paper about “combination therapy” is not necessarily about these two compounds. A 2015 anxiety study compared phenazepam alone in 30 participants with phenazepam plus Selank in 40. It was open-label and did not test Semax. Its results cannot establish a Semax–Selank combination effect.

Our focused PubMed and ClinicalTrials.gov searches did not identify a patient-centered efficacy trial of the exact Semax–Selank combination. That search result is bounded by indexing, terminology and registration; it is not proof that no unpublished study exists. The healthy-volunteer imaging study must also remain visible rather than being incorrectly described as “no comparison research.”

What do safety and regulatory sources add?

Small, short studies provide limited information about uncommon or delayed adverse effects. FDA's current compounding-safety page identifies limited human safety information and concerns involving immune reactions, aggregation and peptide impurities for Semax and Selank. Those concerns do not establish that every exposure causes harm, but they contradict an assurance of established safety. FDA safety information

FDA's 2026 Semax briefing states that neither Semax free base nor acetate is a component of an FDA-approved drug. It recognizes Russian product registration, but that does not confer US approval. This review did not independently verify current Russian product-level registrations for either compound. An advisory briefing, historical overseas use and a currently authorized product label are different kinds of evidence. FDA Semax briefing

For related detail, read the Semax and ADHD evidence guide, Selank evidence guide and neuropeptide research hub.

Review method and source access

Reviewed November 11, 2026. Sources include original English abstracts, full Russian-language 2014 and 2015 journal reports, a full experimental paper and FDA materials. Russian passages were interpreted with AI assistance, not certified translation. Focused searches combined both compound names in PubMed and ClinicalTrials.gov. Full texts were unavailable for some studies; neither this search nor this appraisal is a systematic review or independent clinical review.

Catalog materials are for lawful laboratory research only, not human or veterinary use. Published studies do not verify a supplied lot.